This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPEA7H0NX_M.jpg
Revenues in the biopharmaceutical sector are expected to grow at a CAGR of 7.3% over the next five years to $496.71 billion by 2026.
Thus, we think pharmaceutical companies AbbVie Inc . (NYSE:ABBV), GlaxoSmithKline PLC (GSK), and Gilead Sciences, Inc. (NASDAQ:GILD), which have stable dividend payout histories, are ideal investment bets now.
